Document is current
Any future updates will be listed below
-
Authors
Yada, Koji
Ogiwara, Kenichi
Shimonishi, Naruto
Nakajima, Yuto
Soeda, Tetsuhiro
Kitazawa, Takehisa
Nogami, Keiji
- License Information
-
More Information
Article History
Received: 1 June 2023
Revised: 9 November 2023
Accepted: 16 November 2023
First Online: 19 December 2023
Declarations
:
: KY has received grants, personal fees from Chugai Pharmaceutical Co., Ltd. (Chugai) and had taught a course endowed by Shire and Takeda Pharmaceutical Co. KO has received grants, personal fees from Chugai and had taught a course endowed by CSL Behring. NS teaches a course endowed by CSL Behring. YN has received grant from Takeda Pharmaceutical Co. TS is an employee of Chugai, and is an inventor of the patents relating to emicizumab. TK is an employee of Chugai, owns Chugai’s stocks, and is an inventor of the patents relating to emicizumab. KN has received grants, personal fees, non-financial support from Chugai, personal fees from F. Hoffmann-La Roche Ltd., grants, personal fees and non-financial support from Sysmex Co., grants and personal fees from Takeda Pharmaceutical Co., grants and personal fees from Sanofi S.A, grants, personal fees from CSL Behring Co., grants and personal fees from KM Biologics Co., grants and personal fees from Novo Nordisk A/S, grants and personal fees from Bayer AG, grants and personal fees from Bioverativ Inc, and grants and personal fees from Shire Plc, and is an inventor of the patents relating to emicizumab.
